Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States

In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical infectious diseases Jg. 71; H. 4; S. 1010
Hauptverfasser:	Mase, Sundari, Chorba, Terence, Parks, Samuel, Belanger, Ann, Dworkin, Felicia, Seaworth, Barbara, Warkentin, Jon, Barry, Pennan, Shah, Neha
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 14.08.2020
Schlagworte:	Antitubercular Agents - adverse effects Diarylquinolines - adverse effects Humans Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy United States - epidemiology United States treatment adverse event multidrug-resistant tuberculosis bedaquiline outcome
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!